Danielle Herritt

Danielle Herritt brings 20 years of experience to helping life sciences companies develop and protect their commercial products. She has secured many patents listed in the FDA Orange Book and defended them in PTAB proceedings and Federal Circuit appeals.

Danielle's work for commercial products spans small molecule and small peptide drugs—including multiple blockbusters. These therapies target critical areas such as oncology, pain, addiction, depression, osteoporosis, immune disorders, and gastrointestinal diseases.

Beyond portfolio management, she guides clients through transactional due diligence and resolves disputes with development and clinical partners. She is passionate about building portfolios for small molecule drugs, antibody-drug conjugates, and small peptides, and prides herself on collaborating seamlessly with regulatory and ANDA counsel.

Practice Areas

Representative Matters

• Due diligence for pharmaceutical companies in recent transactions resulting in financings and acquisitions, as well as in initial public offerings.*
• Developing intellectual property portfolios for FDA approved drug products treating pain, addiction, depression, osteoporosis, skin care, GI disorders, and migraines, among others.*
• Representing a client in an ongoing dispute including multiple PTAB challenges both as petitioner and patent owner, several federal circuit appeals, and parallel district court proceedings in three states.*
• Successful resolution of a district court litigation and several PTAB proceedings in the diagnostics space.*
• Representing a printed circuit board fabricator in its prosecution and worldwide licensing of its fabrication portfolio relating to chemical deposition.*
• Representing companies with respect to food allergy diagnostics, pain and addiction drugs, formulations and dosing of approved therapeutic antibody products, diagnostic gels and blood analysis kits, implants for delivery of long-acting drugs, an FDA approved botulinum composition, antibody-drug conjugates, vaccines, and chimeric antigen receptors.*

*matter handled prior to joining Honigman LLP

Prior Experience

• Monsanto, Reformulation Chemist/Chemical Engineer
• Procter & Gamble, Formulation Chemist/Chemical Engineer

Education

Admissions

Court Admissions

Awards

• Chambers USA, Intellectual Property (Massachusetts), 2026
• Managing IP's Top 250 Women in IP
• Super Lawyers, Rising Stars (Intellectual Property; Massachusetts), 2007-2009, 2011
• IAM Patent 1000: The World's Leading Patent Practitioners, 2024-2027

Professional & Community Involvement

• American Chemical Society
• Boston Bar Association
• Boston Patent Law Association
• Women’s Bar Association

Press Releases

Publications

• “Negotiating and Drafting Masterclass: Considerations for Structuring the Deal and the Relevant Documents PostIP Due Diligence”, American Conference Institute, November 15, 2019
• “Life Sciences at the PTAB”, Boston Patent Law Association’s (BPLA) First Annual PTAB Summit, November 2, 2016
• “What Akamai & McKesson Mean for Patent Infringement”, MCLE Webcast Program, October 18, 2012
• “Prolonging Term: Hours, Days, Months, The Rags of Time, Comparative Patent Practice Conference”, Tokyo, Japan, November 16, 2011
• “Patent Reform: US Overhauls Patent System-Will Europe?”, Comparative Patent Practice Conference, Tokyo, Japan, November 16, 2011